“LIMR’s work in cancer and inflammation is an elegant fit with Rockland's antibody portfolio and technology platform … We are proud to bring the unique scientific and commercial opportunities of the LIMR/LDI/Rockland collaboration to the global research community,” James Fendrick, president and CEO of Rockland Immunochemicals, said in a press release about the deal.